Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients

Annals of Oncology

Volumn 20, Issue 1, 2009, Pages 78-83

  Vincenzi, B ^a   Santini, D ^a   Perrone, G ^a   Russo, A ^b,e   Adamo, V ^c   Rizzo, S ^b   Castri, F ^d   Antinori, A ^d   Alloni, R ^a   Crucitti, P F ^a   Morini, S ^a   Rabitti, C ^a   Vecchio, F M ^d   Magistrelli, P ^d   Coppola, R ^a   Tonini, G ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

Ampullary cancer; PML; Survival

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; VATER PAPILLA CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; COHORT STUDIES; COMMON BILE DUCT NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 58949090656     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn558     Document Type: Article

References (30)

1. Howe JR, Klimstra DS, Moccia RD et al. Factors predictive of survival in ampullary carcinoma. Ann Surg 1998; 228: 87-94.
2. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002; 236: 355-368.
3. Todoroki T, Koike N, Morishita Y et al. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol 2003; 10: 1176-1183.
4. Qiao QL, Zhao YG, Ye ML et al. Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg 2007; 31: 137-143.
5. Mehta VK, Fisher GA, Ford JM et al. Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: Preliminary report. Arch Surg 2001; 136: 65-69.
6. Bhatia S, Miller RC, Haddock MG et al. Adjuvant therapy for ampullary carcinomas: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys 2006; 66: 514-519.
7. Achille A, Baron A, Zamboni G et al. Chromosome 5 allelic losses are early events in tumours of the papilla of Vater and occur at sites similar to those of gastric cancer. Br J Cancer 1998; 78: 1653-1660.
8. Scarpa A, Di Pace C, Talamini G et al. Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis. Gut 2000; 4446: 842-848.
9. Moore PS, Missiaglia E, Beghelli S et al. Allelotype of ampulla of Vater cancer: Highly frequent involvement of chromosome 11. J Cancer Res Clin Oncol 2004; 11130: 339-345.
10. Santini D, Vincenzi B, Tonini G et al. Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients. Clin Cancer Res 2005; 11: 3784-3789.
11. Shaknovich R, Yeyati PL, Ivins S et al. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Mol Cell Biol 1998; 18: 5533-5545.
12. Ball HJ, Melnick A, Shaknovich R et al. The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase. Nucleic Acids Res 1999; 27: 4106-4113.
13. Zhong S, Salomoni P, Pandolfi PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol 2000; 2: 85-90.
14. Pandolfi PP. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum Mol Genet 2001; 10: 769-775.
15. Takahashi Y, Lallemand-Breitenbach V, Zhu J, De Thé H. PML nuclear bodies and apoptosis. Oncogene 2004; 12: 2819-2824.
16. Bernardi R, Pandolfi PP. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 2003; 22: 9048-9057.
17. Gurrieri C, Capodieci P, Bernardi R et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 2004; 96: 269-279.
18. Lee HE, Jee CD, Kim MA et al. Loss of promyelocytic leukaemia protein in human gastric cancers. Cancer Lett 2007; 247: 103-109.
19. Rosai J. Appendix E. In Pancreas and Periampulary Region Rosai and Ackerman's Surgical Pathology. Mosby (ed.). 9th edition. Edinburgh 2004; 2953-2954.
20. UICC. TNM Classification of Malignant Tumours. Sobin LH, Wittekind Ch. (eds) 6th edition. Wiley-Liss: New York 2002; 171-176.
21. Falini B, Flenghi L, Fagioli M et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 1997; 90: 4046-4053.
22. Kaplan EL. Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Peto R, Pike MC, Armitage P et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-39.
24. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
25. Sudo T, Murakami Y, Uemura K et al. Prognostic impact of perineural invasion following pancreatoduodenectomy with lymphadenectomy for ampullary carcinoma. Dig Dis Sci 2008; 53: 2281-2286.
26. Ajiki T, Kamigaki T, Hasegawa Y et al. Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater. Hepatogastroenterology 2001; 48: 1266-1270.
27. Santini D, Tonini G, Vecchio FM et al. Prognostic value of bax, bcl-2, p53 and TUNEL staining in patients with radically resected ampullary carcinoma. J Clin Pathol 2005; 58: 159-165.
28. Kim HJ, Sohn TS, Lee KT et al. Expression of cyclooxygenase-2 and its correlation with clinicopathologic factors of ampulla of vater cancer. J Korean Med Sci 2003; 18: 218-224.
29. Santini D, Perrone G, Vincenzi B et al. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann Oncol 2008; 19: 724-728.
30. Zhang W, Chin LT, Chow AS et al. Lack of expression for the suppressor PML in human small cell lung carcinoma. Int J Cancer 2000; 85: 599-605.